How AI is Driving Drug Discovery: Xaira Therapeutics' Marc Tessier Lavigne

Exceptional organizational success stems from a rigorous commitment to people and clarity of purpose, where high-caliber talent is non-negotiable. Marc Tessier-Lavigne, former president of Stanford and Rockefeller University and current CEO of Xaira Therapeutics, emphasizes that maintaining high standards—such as rejecting all candidates in a faculty search when none meet the bar—is essential for fostering innovation. This philosophy extends to his work at Xaira, which aims to transform the historically inefficient drug discovery process. By integrating frontier AI with massive-scale biology, Xaira seeks to move beyond artisanal, trial-and-error methods to design therapeutics for previously "undruggable" targets. This approach addresses the industry's persistent 90% failure rate by shifting from searching for solutions to computationally designing them, ultimately accelerating timelines and reducing the multi-billion dollar costs associated with traditional pharmaceutical development.